iTeos to Present at SVB Securities Global Biopharma Conference

Rhea-AI Summary

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a biopharmaceutical company focused on immuno-oncology therapies, has announced that its CEO, Michel Detheux, will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00 a.m. EST. A live webcast of the presentation will be accessible on the company's website, with an archived replay available for 30 days post-event.

iTeos is developing innovative therapies, including EOS-448, an anti-TIGIT antibody in collaboration with GSK, and inupadenant, an adenosine A2A receptor antagonist entering proof-of-concept trials, targeting cancer immunosuppression.

WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference being held virtually on Tuesday, February 14, 2023 at 10:00 a.m. EST.

A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression, into proof-of-concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.

For further information, please contact:

Investor Contacts:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com

Media Contacts:
media@iteostherapeutics.com

FAQ

When will Michel Detheux present at the SVB Securities Global Biopharma Conference?

Michel Detheux will present on February 14, 2023, at 10:00 a.m. EST.

How can I watch the iTeos Therapeutics presentation?

The presentation can be viewed live via webcast on the iTeos Therapeutics Investors section of their website.

What is EOS-448 in iTeos Therapeutics' pipeline?

EOS-448 is a high-affinity, potent anti-TIGIT antibody designed to enhance anti-tumor responses.

What is inupadenant's role in iTeos Therapeutics' development?

Inupadenant is a next-generation adenosine A2A receptor antagonist targeting cancer immunosuppression, currently progressing into proof-of-concept trials.

Where is iTeos Therapeutics headquartered?

iTeos Therapeutics is headquartered in Watertown, Massachusetts, with a research center in Gosselies, Belgium.